Vice President, Chief Accounting Officer · Heron Therapeutics, Inc. (HRTX)

Lisa Peraza

A named executive officer of Heron Therapeutics in every fiscal year CompBrief holds from FY2020 to FY2021. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2021

$796,755

Salary $339,900Stock awards $247,123

FY2020: $1,578,739

5th of 5 named executive officers at Heron Therapeutics by FY2021 total.

5 named officers on file for Heron Therapeutics, FY2021

Lisa Peraza’s pay file — $29

  • 2 fiscal years of pay, line by line
  • 4 equity grants, each cited to its filing
  • HRTX’s disclosed peer group of 19 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Heron Therapeutics’s whole pay program stands against its peers

  • Heron Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on HRTX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 25, 2022 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Lisa Peraza’s full pay file as a PDF — free

More than this page: up to 10 years of Lisa’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Lisa Peraza compensation by year

Heron Therapeutics Summary Compensation Table · all 2 fiscal years held
In US dollars, as Heron Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2020FY2021
Salary$328,805$339,900
Bonus$0$0
Stock awards$138,855$247,123
Option awards$990,829$75,530
Non-equity incentive$105,683$118,965
Pension and deferred compensation$0$0
All other$14,567$15,237
Total$1,578,739$796,755

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Heron Therapeutics, Inc. DEF 14A filed April 25, 2022, accession 0001564590-22-015345, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Heron Therapeutics, Inc. filed document, accession 0001564590-22-015345. Every figure is read from that document and cited to the page and table it appears in. Filed April 25, 2022.

$1.6M
$797K
FY20
FY21
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2021 year-end
TypeUnvested unitsValue at year-endExercise price
RSU23,424$213,861—
RSU6,625$60,486—
Option12,297—$10.55
Option5,040—$24.97
Option13,200—$25.02
Option72,959—$15.72

Per the Outstanding Equity Awards at Fiscal Year-End table in Heron Therapeutics, Inc.'s FY2021 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

32 Form 4 lines since the FY2021 proxy (filed April 25, 2022)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2024-01-19Grant or award derivative—41,078$0.0041,078
2024-01-19Grant or award derivative—6,846$0.006,846
2024-01-13Tax withholding—756$2.1555,907
2024-01-13Exercise or conversion—1,289—56,663
2024-01-13Exercise or conversion derivative—1,289$0.006,675
2024-01-13Exercise or conversion derivative—552$0.001,656
2024-01-13Exercise or conversion—552—55,374
2023-10-13Exercise or conversion—552—53,750

The 8 most recent of 32 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Heron Therapeutics’s named executive officers, FY2021

as the company reported each
Named executive officerRoleFY2021 total
Barry QuartFormer Chief Executive Officer$5,430,828
Kimberly ManhardExecutive Vice President, Drug Development$1,858,578
John PoyhonenPresident and Chief Commercial Officer$1,841,120
David SzekeresExecutive Vice President, Chief Operating Officer$1,829,431
Lisa Peraza · this pageVice President, Chief Accounting Officer$796,755

The full Heron Therapeutics compensation record

free company brief

This page is one person within Heron Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Heron Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Lisa Peraza's compensation dossier · One-time report. No refunds.